BioMarin Pharmaceutical Inc.'s (BMRN) CEO Jean-Jacques Bienaimé on Q2 2020 Results - Earnings Call TranscriptSeeking Alpha • 08/05/20
BioMarin Pharmaceutical (BMRN) Q2 Earnings and Revenues Beat EstimatesZacks Investment Research • 08/04/20
BioMarin Announces Second Quarter 2020 Total Revenue Growth of 11% to $430 millionPRNewsWire • 08/04/20
Goldman Sachs Sees Big Gains From 7 Biotech & Pharma Conviction Buy Stocks24/7 Wall Street • 07/24/20
BioMarin to Host Second Quarter 2020 Financial Results Conference Call and Webcast on Tuesday, August 4 at 4:30pm ETPRNewsWire • 07/21/20
BioMarin Promotes Company Veteran, Brian R. Mueller, to Executive Vice President, CFOPRNewsWire • 06/29/20
BioMarin Provides Additional Data from Recent 4 Year Update of Ongoing Phase 1/2 Study of Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A in Late-Breaking Oral Presentation at World Federation of Hemophilia Virtual SummitPRNewsWire • 06/17/20
Dow Jones Futures: Stock Market Rally At Key Level As Coronavirus Cases Pick Up; Nvidia, PayPal, ServiceNow, Cloudflare, Biomarin Near Tight Entries; Analyzing TeslaInvestors Business Daily • 06/14/20
Wall Street's best-performing analysts like these 5 stocks right now - amid the market turmoilCNBC • 06/14/20
BioMarin Provides Highlights of 4 Years of Clinical Data from Ongoing Phase 1/2 Study of Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia APRNewsWire • 05/31/20